---
title: "Oxiracetam: Research & Side Effects | BodyHackGuide"
url: https://www.bodyhackguide.co/compound/oxiracetam
description: "Oxiracetam: mechanism, clinical studies & side effects, 216 PubMed results. Compare 1 current vendor prices."
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

# Oxiracetam

Nootropics: https://www.bodyhackguide.co/wiki#cat-nootropics

Status

Approved (Italy)

Evidence

Not graded on a research bench yet

Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E.

Reviewed 27 October 2026

01 Overview

## What Oxiracetam is

It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms.

Read the full overview Show less

The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable.

Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317).

Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470).

Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.

### How it works

Oxiracetam has no single agreed molecular target. Rodent data support a cholinergic component: it reversed scopolamine-induced disruption of passive avoidance and radial maze performance in rats while preventing the associated fall in hippocampal and cortical acetylcholine, with the same bell-shaped dose-effect relationship for both readouts (PMID: 2602443). It also acts on glutamate signaling. In rat hippocampal slices it prevented kynurenate antagonism of NMDA-evoked noradrenaline release in an assay that also responds to glycine-site and GABA-B ligands, which points to an allosteric action on the NMDA receptor complex (PMID: 9336311); the same effect appeared in human neocortical slices (PMID: 10381808). In APP/PS1 transgenic mice, oxiracetam slowed desensitization of the AMPA receptor GluA1 and GluA2 subunits and increased excitatory postsynaptic current frequency and amplitude in hippocampus (PMID: 41739317).

### Studied for

- Cognitive enhancement
- Vascular cognitive impairment
- Traumatic brain injury
- Nootropics

### Benefits listed

- Antagonized scopolamine-induced amnesia and the associated fall in hippocampal and cortical acetylcholine in rats (PMID: 2602443)
- Prevented mecamylamine-induced impairment of active avoidance learning in mice (PMID: 2356212)
- Facilitated two-way shuttle avoidance acquisition in normal mice (PMID: 3244203)
- S-oxiracetam, and not R-oxiracetam, relieved spatial learning and memory impairment and reduced white matter lesions in rats with chronic cerebral hypoperfusion (PMID: 28855592)

Show 2 more Show less

- Improved cognitive scores versus placebo over 12 weeks in 289 patients with degenerative, multi-infarct or mixed dementia (PMID: 2693996)
- Higher Loewenstein cognitive assessment scores than placebo at 90 days for the single enantiomer L-oxiracetam, an advantage not demonstrated for the racemate, in a 590-patient phase 3 trial in mild to moderate traumatic brain injury (PMID: 41381424)

02 Research

Free with email

## What the research shows

No research bench grades Oxiracetam yet. Benches compare compounds people pair, with the evidence for each.

### Unlock the research summary

Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

- A summary of the key research
- Safety and side effects
- A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in (https://www.bodyhackguide.co/auth)

03 Safety

## Oxiracetam side effects and interactions

### Side effects

Not in our record

Our record lists no side effects for Oxiracetam. That means none are recorded here, not that there are none. The Research section has the written safety notes.

### Who should not use it

Contraindications

Renal impairment is the main pharmacokinetic caution: oxiracetam is excreted essentially unchanged by the kidney and its terminal half-life rose from about 8 hours to as much as 68 hours as creatinine clearance fell (PMID: 2253654; PMID: 6519128). A pilot study found that concurrent carbamazepine or valproic acid shortened the oxiracetam half-life, although oxiracetam did not alter antiepileptic drug serum concentrations (PMID: 2108837). No human pregnancy or lactation safety data have been published; in pregnant rats, radiolabeled oxiracetam crossed the placenta into fetal tissue reversibly and to a limited extent (PMID: 1499599).

### Interactions

Not in our record

Our record lists no interactions for Oxiracetam. That means none are recorded here, not that none exist.

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

Order Bloodwork (https://anabolicinsights.ai/?ref=nwm2zjb)

04 Dosing

Free with email

## Dosing

No dose on record

Our record lists no dose for Oxiracetam. This section holds what it does list.

### Unlock the Dosing section

- Route

05 Prices

## Oxiracetam prices

1 listing from 1 vendor, opening in the Featured order.

Pack prices

$74.99

Lowest per mg

$2.50/g

Vendors

1

Listings

1 (capsule)

Prices as the vendors list them, last recorded 7 September 2026.

Form

Sort

| Vendor | Product | Price | Buy |
| --- | --- | --- | --- |
| Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/uploads/2026/10/disguised-logo-3x.webp) Disguised Alpha: https://www.bodyhackguide.co/vendors/disguised-alpha | Oxiracetam 500 mg capsules (60) capsule, 60 capsules (500 mg) In stock | $2.50/g $74.99 Lowest per mg | Buy Oxiracetam 500 mg capsules (60) at Disguised Alpha: https://disguisedalpha.com/product/oxiracetam/?coupon=reddit |

Vendors selling Oxiracetam(1: trust score, certificates, payment, shipping)

- Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha)1 listing, from $74.99
  Trust Score 50/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK

Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors (https://www.bodyhackguide.co/vendors/scorecard)

Review Oxiracetam

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Oxiracetam.

06 Chemistry

## Chemistry and structure

Molecular formula

C6H10N2O3

Molecular mass

158.16 g/mol

CAS number

62613-82-5

Half-life

About 8 hours in healthy adults. Mean terminal half-life was 7.7 hours in healthy non-geriatric subjects and 12.3 hours in elderly patients after oral dosing (PMID: 2253653), and 10.6 to 68.1 hours in patients with renal impairment, correlating with creatinine clearance (PMID: 2253654). More than 90 percent of an intravenous dose is recovered unchanged in urine within 48 hours, and absolute oral bioavailability was 75 percent in healthy volunteers (PMID: 6519128).

View on PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/4626)

07 Related

## Related to Oxiracetam

### In the same category

- 9-Me-BC (9-Methyl-β-carboline)Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].: https://www.bodyhackguide.co/compound/9-mbc
- AniracetamApproved Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.: https://www.bodyhackguide.co/compound/aniracetam
- Bemethyl (bemitil)Approved Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.: https://www.bodyhackguide.co/compound/bemethyl
- BPAPPreclinical BPAP, or (-)-BPAP, is a synthetic benzofuran compound, (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, developed by Joseph Knoll's group at Semmelweis University in Budapest with Fujimoto Pharmaceutical Corporation of Osaka as a potential successor to selegiline (deprenyl).: https://www.bodyhackguide.co/compound/bpap
- BromantaneRussia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.: https://www.bodyhackguide.co/compound/bromantane
- CaffeineApproved Caffeine (1,3,7-trimethylxanthine) is a natural methylxanthine alkaloid found in the seeds, fruits, leaves, and bark of over 60 plant species — most notably Coffea (coffee), Camellia sinensis (tea), Theobroma cacao (cacao), Paullinia cupana (guaraná), Ilex paraguariensis (yerba mate), and Cola acuminata (kola nut).: https://www.bodyhackguide.co/compound/caffeine

All compounds (https://www.bodyhackguide.co/wiki)

### Compare Oxiracetam

- Alternatives to Oxiracetam: https://www.bodyhackguide.co/alternatives-to/oxiracetam

### Research tools

- Peptide Calculator Reconstitution and syringe units: https://www.bodyhackguide.co/tools/reconstitution
- Reconstitution Guide How to mix, step by step: https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides
- Nasal Spray Calc mL per actuation: https://www.bodyhackguide.co/tools/intranasal
- Half-Life Visualizer Decay curves: https://www.bodyhackguide.co/tools/halflife

All articles (https://www.bodyhackguide.co/blog)

08 Questions

## Frequently asked questions

What is Oxiracetam used for in research?

Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms.

What forms does Oxiracetam come in?

Oxiracetam is available in capsule form.

How do I compare Oxiracetam vendors?

Compare prices, payment methods, shipping, and COA scores across 1 vendor.

How many vendors sell Oxiracetam, and what does it cost per mg?

1 of the vendors BodyHackGuide tracks list Oxiracetam (1 listing). Among BodyHackGuide's Oxiracetam listings recorded as in stock with a milligram count, the lowest price per milligram is $2.50/g at Disguised Alpha and the median is $2.50/g. The Oxiracetam prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Oxiracetam listing is dated 7 September 2026.

Which vendors have third-party COAs for Oxiracetam on file at BodyHackGuide?

BodyHackGuide holds no third-party certificate records for Oxiracetam. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor.

Free 2026 Peptide Cheat Sheet (PDF)

38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download)

BodyHackGuide (https://www.bodyhackguide.co/)

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved.

- Terms: https://www.bodyhackguide.co/terms
- Privacy: https://www.bodyhackguide.co/privacy

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://www.bodyhackguide.co/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Compounds",
        "item": "https://www.bodyhackguide.co/compare"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Oxiracetam"
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "Product",
    "name": "Oxiracetam",
    "description": "Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms. The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable. Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317). Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470). Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.",
    "url": "https://www.bodyhackguide.co/compound/oxiracetam",
    "image": "https://www.bodyhackguide.co/og-image.png",
    "brand": {
      "@type": "Brand",
      "name": "Research Compound"
    },
    "offers": {
      "@type": "AggregateOffer",
      "lowPrice": "74.99",
      "highPrice": "74.99",
      "priceCurrency": "USD",
      "offerCount": "1",
      "availability": "https://schema.org/InStock",
      "offers": [
        {
          "@type": "Offer",
          "price": "74.99",
          "priceCurrency": "USD",
          "availability": "https://schema.org/InStock",
          "itemCondition": "https://schema.org/NewCondition",
          "url": "https://disguisedalpha.com/product/oxiracetam/?coupon=reddit",
          "seller": {
            "@type": "Organization",
            "name": "Disguised Alpha",
            "url": "https://disguisedalpha.com/?coupon=reddit"
          },
          "name": "Oxiracetam 30000mg capsule"
        }
      ]
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "Oxiracetam",
    "description": "Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms. The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable. Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317). Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470). Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.",
    "lastReviewed": "2026-10-27T07:11:00+00:00",
    "url": "https://www.bodyhackguide.co/compound/oxiracetam",
    "author": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "reviewedBy": {
      "@type": "Person",
      "name": "BioChonch",
      "url": "https://www.bodyhackguide.co/about",
      "jobTitle": "Founder & Lead Researcher",
      "sameAs": [
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher"
      ],
      "worksFor": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      }
    },
    "publisher": {
      "@type": "Organization",
      "name": "BodyHackGuide",
      "url": "https://www.bodyhackguide.co"
    },
    "mainContentOfPage": {
      "@type": "WebPageElement",
      "cssSelector": "main"
    },
    "about": {
      "@type": "Drug",
      "name": "Oxiracetam",
      "alternateName": [
        "ISF 2522",
        "CGP 21690E",
        "Neuromet",
        "Hydroxypiracetam",
        "S-oxiracetam",
        "L-oxiracetam",
        "4-hydroxy-2-oxo-1-pyrrolidineacetamide"
      ],
      "description": "Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms. The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable. Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317). Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470). Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.",
      "activeIngredient": "Oxiracetam",
      "administrationRoute": "Oral, Intravenous infusion",
      "mechanismOfAction": "Oxiracetam has no single agreed molecular target. Rodent data support a cholinergic component: it reversed scopolamine-induced disruption of passive avoidance and radial maze performance in rats while preventing the associated fall in hippocampal and cortical acetylcholine, with the same bell-shaped dose-effect relationship for both readouts (PMID: 2602443). It also acts on glutamate signaling. In rat hippocampal slices it prevented kynurenate antagonism of NMDA-evoked noradrenaline release in an assay that also responds to glycine-site and GABA-B ligands, which points to an allosteric action on the NMDA receptor complex (PMID: 9336311); the same effect appeared in human neocortical slices (PMID: 10381808). In APP/PS1 transgenic mice, oxiracetam slowed desensitization of the AMPA receptor GluA1 and GluA2 subunits and increased excitatory postsynaptic current frequency and amplitude in hippocampus (PMID: 41739317).",
      "dosageForm": "capsule",
      "legalStatus": "Approved (Italy)"
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "FAQPage",
    "mainEntity": [
      {
        "@type": "Question",
        "name": "What is Oxiracetam used for in research?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms. The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable. Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317). Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470). Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs."
        }
      },
      {
        "@type": "Question",
        "name": "What forms does Oxiracetam come in?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Oxiracetam is available in capsule form."
        }
      },
      {
        "@type": "Question",
        "name": "How do I compare Oxiracetam vendors?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor."
        }
      },
      {
        "@type": "Question",
        "name": "How many vendors sell Oxiracetam, and what does it cost per mg?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "1 of the vendors BodyHackGuide tracks list Oxiracetam (1 listing). Among BodyHackGuide's Oxiracetam listings recorded as in stock with a milligram count, the lowest price per milligram is $2.50/g at Disguised Alpha and the median is $2.50/g. The Oxiracetam prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Oxiracetam listing is dated 7 September 2026."
        }
      },
      {
        "@type": "Question",
        "name": "Which vendors have third-party COAs for Oxiracetam on file at BodyHackGuide?",
        "acceptedAnswer": {
          "@type": "Answer",
          "text": "BodyHackGuide holds no third-party certificate records for Oxiracetam. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor."
        }
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "@id": "https://www.bodyhackguide.co#organization",
    "name": "BodyHackGuide",
    "alternateName": "BHG",
    "url": "https://www.bodyhackguide.co",
    "logo": {
      "@type": "ImageObject",
      "url": "https://www.bodyhackguide.co/logo.png",
      "width": 512,
      "height": 512
    },
    "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.",
    "foundingDate": "2024",
    "founder": {
      "@id": "https://www.bodyhackguide.co/about#person"
    },
    "sameAs": [
      "https://reddit.com/r/BodyHackGuide",
      "https://reddit.com/r/BrainHackGuide",
      "https://reddit.com/r/Biohackingher",
      "https://discord.gg/Mhq5UdRYBA"
    ],
    "knowsAbout": [
      "Peptide research",
      "Nootropic research",
      "Biohacking",
      "Compound dosing",
      "Vendor transparency"
    ],
    "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
    "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
    "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
  }
]
```